Abstract
In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.
Keywords: IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.
Current Pharmaceutical Design
Title:Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Volume: 22 Issue: 18
Author(s): Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.
Abstract: In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.
Export Options
About this article
Cite this article as:
Katsiki Niki, G. Athyros Vasilios, Karagiannis Asterios and P. Mikhailidis Dimitri, Statins and Type 2 Diabetes Mellitus: An Update After 1 Year, Current Pharmaceutical Design 2016; 22 (18) . https://dx.doi.org/10.2174/1381612822666160125114626
DOI https://dx.doi.org/10.2174/1381612822666160125114626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
Current Pharmaceutical Design Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Current Signal Transduction Therapy A Comparative Assessment of Metabolic Syndrome and its Association with Vitamin D and Other Risk Factors in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Improved Insulin Resistance through Cajanus cajan extract in Gestational Diabetes Mellitus of Wistar Rat
Current Women`s Health Reviews Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds Application of NKT Cells in Immunotherapy
Current Immunology Reviews (Discontinued) Synthesis and Immunosuppressive Activity of New Mycophenolic Acid Derivatives
Medicinal Chemistry Preface
Current Diabetes Reviews A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study
Current HIV Research Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Liver-Directed Gene Therapy with Helper-Dependent Adenoviral Vectors: Current State of the Art and Future Challenges
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety